Who we are?

We are a biotechnological company applying immunotherapeutic solutions addressing unmet medical needs in the main veterinarian and human markets

  • BDi Health owns an antigen display technology with a strong potential to boost and direct specific immune responses, humoral or cellular already validated in two in-vivo proof of concepts

  • We have our own product portfolio derived from our patented technology; but also we are licensing technology in the animal field to industrial end-users that are able to support the development and market the products

The VLP Technology

Our technology is a patented and proprietary antigen-display nanoplatform based on Virus-Like Particles (VLPs). These are empty and non infectious structures mimicking real viruses and then capable to induce strong immune responses. We are able to incorporate pathology-associated antigens into VLPs generating chimeric nanoparticles (Ch-VLPs) that can be designed to specifically induce either humoral or cellular responses.

Advantages of VLPbio technology:

Biosafety

VLPs mimic real viruses but they are not infectious avoiding the issues related to pathogen inactivation and simplifying vaccines security tests

Compilance (DIVA)

High flexibility

Vaccines can be constituted by a formulation of different Ch-VLPs monocomponents displaying different antigens (cellular, humoral or both)

Low cost production

Syntetic Design

Possibility to design synthetic antigenic consensus sequences covering different pathogen strains

Co-development of diagnostic tests

Our Products

BDI Products

PRRSVax

Prophylactic vaccine against porcine reproductive respiratory syndrome.

Others

Circovirus y BDV

CerVivax

Propietary therapeutic Vaccine against Cervical Intrauterine Neoplastia based on
Q-VLP propietary technology

BDI Products

We offer customized solutions contact us to discuss your project